Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3β inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 4021-4031

  Kuo, Gee Hong ^a   Prouty, Catherine ^a   DeAngelis, Alan ^a   Shen, Lan ^a   O'Neill, David J ^a   Shah, Chandra ^a   Connolly, Peter J ^a   Murray, William V ^a   Conway, Bruce R ^a   Cheung, Peter ^a   Westover, Lori ^a   Xu, Jun Z ^a   Look, Richard A ^a   Demarest, Keith T ^a   Emanuel, Stuart ^a   Middleton, Steven A ^a   Jolliffe, Linda ^a   Beavers, Mary Pat ^a   Chen, Xin ^a  

^a Drug Discovery Raritan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11,13,14,16,17,19,20,22,23 DECAHYDRO 9,4:24,29 DIMETHENO 1H DIPYRIDO[2,3 N:3',2' T]PYRROLO[3,4 Q][1,4,7,10,13,22]TETRAOXADIAZACYCLOTETRACOSINE 1,3(2H) DIONE; 6,7,9,10,12,13,15 OCTAHYDRO 23H 5,26:17,22 DIMETHENO 5H DIPYRIDO[2,3 K:3',2' Q]PYRROLO[3,4 N][1,4,7,10,19]TRIOXADIACYCLOHENICOSINE 23,25(24H) DIONE; ADENOSINE TRIPHOSPHATE; BIS 7 AZAINDOLYLMALEIMIDE DERIVATIVE; CASEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; LITHIUM CHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PALLADIUM; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RUBOXISTAURIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC 50; MOLECULAR INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ADIPOCYTES; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; DRUG DESIGN; ENZYME INHIBITORS; ETHERS, CYCLIC; GLYCOGEN SYNTHASE KINASE 3; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MALEIMIDES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0141567462     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030115o     Document Type: Article

References (54)

1. Embi, N.; Rylatt, D. B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle: separation from cAMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107, 519-527.
2. Welsh, G. I.; Proud, C. G. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initation factor eIF-2B. Biochem. J. 1993, 294, 625-629.
3. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9, 2431-2438.
4. Grimes, C. A.; Jope, R. S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 2001, 65, 391-426.
5. Eldar-Finkelman, H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 2002, 8 (3), 126-132.
6. Kaidanovich, O.; Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin. Ther. Targets 2002, 6 (5), 555-561.
7. (a) Lovestone, S.; Reynolds, C. H.; Latimer, D.; Davis, D. R.; Anderton, B. H.; Gallo, J.-M.; Hanger, D.; Mulot, S.; Marquardt, B.; Stabel, S.; Woodgett, J. R.; Miller, C. C. J. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 1994, 4, 1077-1086.
8. (b) Pap, M.; Cooper, G. M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/akt cell survival pathway. J. Biol. Chem. 1998, 273, 19929-19954.
9. (c) Lucas, J. J.; Hernandez, F.; Gomez-Ramos, P.; Moran, M. A.; Hen, R.; Avila, J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 2001, 20, 27-39.
10. Cross, D.; Cubert, A. A.; Chalmers, K. A.; Facci, L.; Skaper, S. D.; Reith, A. D. Selective small molecule inhibitors of glycogen synthase kinase-3 activity protects primary neurons from death. J. Neurochem. 2001, 77, 94-102.
11. Castro, A.; Martinez, A. Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders. Expert Opin. Ther. Pat. 2000, 10, 1519-1527.
12. Phiel, C. J.; Klein, P. S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 789-813.
13. Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M.-S.; Jin, O.; Woodgett, J. R. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000, 406, 86-90.
14. Bray, A. M.; Schultz, P.; Ring, D. B.; Harrison, S. D. Purine inhibitors of glycogen synthase kinase (GSK3). Chiron Corp. Patent WO9816528, 1998.
15. Dorronsoro, I.; Castro, A.; Martinez, A. Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? Expert Opin. Ther. Pat. 2002, 12 (10), 1527-1536.
16. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22 (4), 373-384.
17. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45, 1292-1299.
18. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders, M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-Anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
19. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D.; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7 (10), 793-803.
20. Faul, M. M.; Sullivan, K. A.; Winneroski, L. L. A general approach to the synthesis of bisindolylmaleimides: synthesis of staurosporine aglycone. Synthesis 1995, 1511-1516.
21. Merz, A.; Karl, A.; Futterer, T.; Stacherdinger, N.; Schneider, O.; Lex, J.; Luboch, E.; Biernat, J. F. Synthesis and reactions of crown ether-bridged stilbenes. Liebigs Ann. Chem. 1994, 12, 1199-1209.
22. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A.; Sullivan, K. A.; Gillig, J. R.; Neel, D. A.; Rito, C. J.; Jirousek, M. R. Macrocyclic bisindolylmaleimides: synthesis by inter- and intramolecular alkylation. J. Org. Chem. 1998, 63, 1961-1973.
23. Kelly, T. A.; McNeil, D. W.; Rose, J. M.; David, E.; Shih, C.-K.; Grob, P. M. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl-and 2-azaindol-3-yl-dipyridodiazepinones. J. Med. Chem. 1997, 40, 2430-2433.
24. Fujita, M.; Oka, H.; Ogura, K. Palladium(0)/LiCl promoted cross-coupling reaction of (4-pyridyl)stannanes and aromatic bromides: easy access to poly-(4-pyridyl)-substituted aromatics. Tetrahedron Lett. 1995, 36, 5247-5250.
25. For the less readily available maleimide bromide or maleimide triflate being used in Pd-catalyzed cross-coupling reaction, see the following. (a) Terpin, A.; Winklhofer, C.; Schumann, S.; Steglich, W. Synthesis and cyclization of didemnimide C and its imidazol-1-yl isomer. Tetrahedorn 1998, 54, 1745-1752.
26. (b) Neel, D. A.; Jirousek, M. R.; McDonald, J. H., III. Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction. Bioorg. Med. Chem. Lett. 1998, 8, 47-50.
27. Recently, it was reported that condensation of a 7-azaindole Grignard reagent with the less readily available 3,4-dibromo-N-methylmaleimide gave bis-7-azaindolylmaleimide. Routier, S.; Ayerbe, N.; Me'rour, J.-Y.; Coudert, G. ; Bailly, C.; Pierr'e, A.; Pfeiffer, B.; Caignard, D.-H.; Renard, P. Synthesis and biological evaluation of 7-azaindolocarbazoles. Tetrahedron 2002, 58, 6621-6630.
28. Hu, H. Recent discovery and development of selective protein kinase C inhibitors. Drug Discovery Today 1996, 1 (10), 438-447.
29. Jirousek, M. R.; Gillig, J. R.; Gonzalez, C. M.; Heath, W. F.; McDonald, J. H., III; Neel, D. A.; Rito, C. J.; Singh, U.; Stramm, L. E.; Melikian-Badalian, A.; Baevsky, M.; Ballas, L. M.; Hall, S. E.; Winneroski, L. L.; Faul, M. M. (S)-13-[(Dimethylamino)-methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3-(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ. J. Med. Chem. 1996, 39, 2664-2671.
30. Wilkinson, S. E.; Parker, P. J.; Nixon, J. S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J. 1993, 294, 335-337.
31. Dekker, L. V.; Parker, P. J. Protein kinase C-a question of specificity. Trends Biol. Sci. 1994, 19, 73-77.
32. (a) Leost, M.; Schultz, C.; Link, A.; Yong-Zhong, W.; Biernat, J.; Mandelkow, E.-M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5944.
33. (b) Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y. Z.; Mandelkow, E. M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-260.
34. (c) Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J.-m.; Meijer, L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46, 222-236.
35. Hers, I.; Tavare, J. M.; Denton, R. M. The protein kinase C inhibitors bisindolylmaleimide I (GF109203x) and IX (Ro31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999, 460, 433-436.
36. Kennedy, M. B.; Mcguinness, T.; Greengard, P. Calcium calmodulin dependent protein kinase assay. J. Neurosci. 1983, 3, 818-831.
37. The kinetic studies that demonstrated compounds 28 and 29 are ATP competitive inhibitors will be published in a separate manuscript.
38. Nyfeler, F.; Walter, P. Effect of lithium on glycogen synthesis in hepatocytes from rat liver. FEBS Lett. 1979, 108, 197-199.
39. Stambolic, V.; Ruel, L.; Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signaling in intact cells. Curr. Biol. 1996, 6, 1664-1668.
40. Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8455-8459.
41. Dajani, R.; Fraser, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H. Crystal structure of glycogen synthase kinase-3 beta. Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001, 105, 721-732.
42. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 1997, 4, 796-801.
43. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structure analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure (London) 1999, 7, 651-661.
44. http://pkr.sdsc.edu/html/index.shtml.
45. Hanks, S.; Quinn, A. M. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Methods Enzymol. 1991, 200, 38-62.
46. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
47. SYBYL, version 6.9; Tripos Inc., 1699 South Hanley Rd, St. Louis, MO, 63144.
48. Needleman, S. B.; Wunsch, C. D. General method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 1970, 48, 443-453.
49. Chang, G.; Guida, W. C.; Still, W. C. An internal-coordinate Monte Carlo method for searching conformational space. J. Am. Chem. Soc. 1989, 111, 4379-4386.
50. MacroModel; Schrodinger, 1500 SW First Avenue, Suite 1180, Portland, OR 97201.
51. Glide; Schrodinger, 1500 SW First Avenue, Suite 1180, Portland, OR 97201.
52. For the full description of GlideScore, see the following. Scoring in Glide. In First Discovery Technical Notes; Schrodinger: Portland, OR, 2002; Chapter 5, p 48.
53. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
54. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.